Link
- Argentinean Network of Women Living with HIV-AIDS
- Asia Pacific Network of People Living with HIV/AIDS
- bilaterals.org
- Cambodian People Living with HIV/AIDS Network (CPN+)
- Delhi Network of Positive People (DNP+)
- Essentialdrugs.org
- FACEBOOK PAGE: Stop the EU India Free Trade Agreement
- FTA Malaysia
- Health Action International – Asia Pacific
- Intellectual Property Watch
- Lawyers Collective HIV/AIDS Unit
- MSF Access Campaign
- National Association of People Living with HIV and AIDS in Nepal (NAPN)
- Public Citizen
- Stop Peru FTA
- Thai Network of People Living with HIV/Aids (TNP+)
- Third World Network
Take Action
Archives
-
Recent Posts
- The Cost of Price: Why and How to Get Beyond Intellectual Property Internalism
- WHA 65 adopted the resolution for way forward on CEWG report on R&D
- Corporations Win Big in Battle Against Investment Regulation
- US and EU Derailing Ten-year Process to Create Health Research & Development Convention
- MSF: Update on debates at World Health Assembly on a possible R&D convention, 23 May 2012
Categories
Tag Archives: Pharmaceutical industry
Sarah Boseley: How the war on fake drugs risks harming the poor
Source: The Guardian, 2.2.2011 A new Oxfam report warns that the strategy against counterfeit medicines suits the interests of big pharma and rich countries, but will not safeguard the poor against fake and sub-standard drugs, and could hinder their access … Continue reading
MSF Statement: Johnson & Johnson/ Tibotec AIDS Drug Licenses Leave Out Too Many Patients
Geneva, 28 January 2011 – Licenses just agreed between three generic manufacturers and pharmaceutical company Tibotec, owned by Johnson & Johnson, will keep a promising new AIDS medicine out of the hands of many patients across the developing world, the … Continue reading
Posted in Other
Tagged Generic drug, HIV/Aids, Médecins Sans Frontières, Pharmaceutical industry
1 Comment
Press: Don’t Swallow This Pill
Source: Times of India, 19.1.2011, by Unni Karunakara Are the European Union and its multinational pharmaceutical companies now pressuring the Indian prime minister’s office? In recent months, as negotiators from India and Europe have been thrashing out the details of … Continue reading
Posted in EU-India FTA
Tagged EU, FTA, Generic drug, HIV/Aids, India, Pharmaceutical industry
Leave a comment
Press: India: Govt may limit FDI in pharma sector at 49%
Source: The Times of India, 14.01.2011, by Rupali Mukherjee “MUMBAI: The government may soon take a decision to cap foreign direct investment in the pharma sector at 49% from the 100% allowed now. Sources say there is also a thinking … Continue reading
Press: EU push for liberal patents finds favour with PMO
KG NARENDRANATH, Wednesday, Jan 12, 2011, The Financial Express New Delhi: Hard lobbying by the European Union (EU), home to many of the world’s largest pharmaceutical firms like Novartis, Sanofi-Aventis and Roche, has struck a chord with the Prime Minister’s Office (PMO), … Continue reading
Posted in EU-India FTA
Tagged EU, FTA, India, Intellectual property, Manmohan Singh, Pharmaceutical industry, TRIPS, WTO
Leave a comment
Concern over purchase of generic companies by MNCs
Jan 11 2011, New Delhi, Indian Express The purchase of country’s major generic drug producers by multi-national corporations is a “cause of concern” as it may result in reduced competition and “endanger” the availability of low cost drugs, a report … Continue reading
The 2011 Drug Patent ‘Cliff’ And The Evolution Of IP Valuation
By Liza Porteus Viana , 11 Jan 2011, Intellectual Property Watch In today’s global economy, there is an increasing convergence of intellectual property and finance. Wall Street is grappling with how, exactly, to recognise the true value of a firm’s intellectual property, … Continue reading
Press: Natco Pharma Seeks ‘Compulsory License’ For Copy Of Pfizer Drug
Source: in.advfn.com, 06.12.2011 Natco Pharma Ltd. (524816.BY) said Wednesday it has informed Pfizer Inc. (PFE) that it wants to make and sell a low-cost generic version of the U.S. company’s maraviroc for treating the HIV infection under a so-called “compulsory … Continue reading
Pharma (Indian): Walking the tightrope between affordability, profits
P.T. Jyothi Datta, Mumbai, Dec. 30 2010 It could well turn out to be a significant year for the over Rs 1-lakh-crore (Indian) pharmaceutical industry, if clarity dawns on contentious issues facing the sector. Be it implementation of intellectual property laws, … Continue reading
Posted in EU-India FTA
Tagged Generic drug, India, Intellectual property, Pharmaceutical industry
Leave a comment
Press: Patent office rejects Abbott Labs plea for expensive AIDS drug
Source: DNA, 04.01.2011, by Priyanka Golikeri HIV/AIDS patients across the world can rejoice on this: the Mumbai Patent Office has rejected a patent application on a crucial medicine by multinational company Abbott Laboratories. This rejection allows low cost generic versions … Continue reading
Posted in HIV/Aids, Patent Opposition
Tagged Generic drug, HIV/Aids, India, Intellectual property, Patent, Pharmaceutical industry
Leave a comment
